Human CGMP-dependent protein kinase 1 (PRKG1) ELISA Kit | AE60047HU

Human CGMP-dependent protein kinase 1 (PRKG1) ELISA Kit | AE60047HU | Gentaur UK, US & Europe Distribution

Species Reactivity: Human (Homo sapiens)

Abbreviation: PRKG1

Alternative Name: RP11-346D6.1; CGKI; DKFZp686K042; FLJ36117; MGC71944; PGK; PKG; PRKG1B; PRKGR1B; cGKI-BETA; cGKI-alpha; protein kinase; cGMP-dependent; regulatory; type I; beta

Application: ELISA

Range: Request Information

Sensitivity: Request Information

Intra-Assay: ≤4.6%

Inter-Assay: ≤8.3%

Recovery: 0, 98

Sample Type: Serum, Plasma, Other biological fluids

Detection Method: Sandwich

Analysis Method : Quantitive

Test Principale: This assay employs a two-site sandwich ELISA to quantitate PRKG1 in samples. An antibody specific for PRKG1 has been pre-coated onto a microplate. Standards and samples are pipetted into the wells and anyPRKG1 present is bound by the immobilized antibody. After removing any unbound substances, a biotin-conjugated antibody specific for PRKG1 is added to the wells. After washing, Streptavidin conjugated Horseradish Peroxidase (HRP) is added to the wells. Following a wash to remove any unbound avidin-enzyme reagent, a substrate solution is added to the wells and color develops in proportion to the amount of PRKG1 bound in the initial step. The color development is stopped and the intensity of the color is measured.

Product Overview: Two main forms of cGK have been identified: a soluble form designated type I and an intrinsic membrane-bound form designated type II. Prkg1 knockout mice showed impaired platelet responses to VWF or low doses of thrombin and prolonged bleeding time. Human platelet aggregation induced by VWF or low-dose thrombin was inhibited by PRKG1 inhibitors but enhanced by cGMP. Furthermore, a cGMP-enhancing agent, sildenafil, promoted VWF- or thrombin-induced platelet aggregation. The cGMP-stimulated platelet responses were biphasic, consisting of an initial transient stimulatory response that promoted platelet aggregation and a subsequent inhibitory response that limited the size of thrombi.

Stability: The stability of ELISA kit is determined by the loss rate of activity. The loss rate of this kit is less than 5% within the expiration date under appropriate storage condition. The loss rate was determined by accelerated thermal degradation test. Keep the kit at 37°C for 4 and 7 days, and compare O.D.values of the kit kept at 37°C with that of at recommended temperature. (referring from China Biological Products Standard, which was calculated by the Arrhenius equation. For ELISA kit, 4 days storage at 37°C can be considered as 6 months at 2 - 8°C, which means 7 days at 37°C equaling 12 months at 2 - 8°C) .